Lineage Cell Therapeutics Statistics
Total Valuation
LCTX has a market cap or net worth of $176.00 million. The enterprise value is $135.64 million.
| Market Cap | 176.00M |
| Enterprise Value | 135.64M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LCTX has 188.82 million shares outstanding. The number of shares has increased by 7.51% in one year.
| Shares Outstanding | 188.82M |
| Shares Change (YoY) | +7.51% |
| Shares Change (QoQ) | +4.51% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 49.79% |
| Float | 146.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.99 |
| Forward PS | 13.18 |
| PB Ratio | 2.43 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.71, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.71 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.20% and return on invested capital (ROIC) is -32.72%.
| Return on Equity (ROE) | -34.20% |
| Return on Assets (ROA) | -22.10% |
| Return on Capital (ROIC) | -32.72% |
| Revenue Per Employee | $117,691 |
| Profits Per Employee | -$347,882 |
| Employee Count | 68 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.89% in the last 52 weeks. The beta is 1.31, so LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -33.89% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 45.22 |
| Average Volume (20 Days) | 940,327 |
Short Selling Information
The latest short interest is 12.92 million, so 6.84% of the outstanding shares have been sold short.
| Short Interest | 12.92M |
| Short Previous Month | 12.37M |
| Short % of Shares Out | 6.84% |
| Short % of Float | 8.83% |
| Short Ratio (days to cover) | 11.53 |
Income Statement
In the last 12 months, LCTX had revenue of $8.00 million and -$23.66 million in losses. Loss per share was -$0.13.
| Revenue | 8.00M |
| Gross Profit | 7.35M |
| Operating Income | -24.75M |
| Pretax Income | -23.66M |
| Net Income | -23.66M |
| EBITDA | -22.96M |
| EBIT | -23.66M |
| Loss Per Share | -$0.13 |
Balance Sheet
The company has $43.62 million in cash and $3.25 million in debt, giving a net cash position of $40.37 million or $0.21 per share.
| Cash & Cash Equivalents | 43.62M |
| Total Debt | 3.25M |
| Net Cash | 40.37M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 72.40M |
| Book Value Per Share | 0.38 |
| Working Capital | 28.83M |
Cash Flow
In the last 12 months, operating cash flow was -$23.11 million and capital expenditures -$524,000, giving a free cash flow of -$23.63 million.
| Operating Cash Flow | -23.11M |
| Capital Expenditures | -524,000 |
| Free Cash Flow | -23.63M |
| FCF Per Share | -$0.13 |
Margins
Gross margin is 91.88%, with operating and profit margins of -309.28% and -295.59%.
| Gross Margin | 91.88% |
| Operating Margin | -309.28% |
| Pretax Margin | -295.59% |
| Profit Margin | -295.59% |
| EBITDA Margin | -286.89% |
| EBIT Margin | -295.59% |
| FCF Margin | -295.28% |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.51% |
| Shareholder Yield | -7.51% |
| Earnings Yield | -13.44% |
| FCF Yield | -13.43% |
Analyst Forecast
The average price target for LCTX is $6.50, which is 597.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.50 |
| Price Target Difference | 597.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 76.94% |
| EPS Growth Forecast (5Y) | 2.02% |
Stock Splits
The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
LCTX has an Altman Z-Score of -2.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.56 |
| Piotroski F-Score | 2 |